In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Azur Pharma plc

http://www.azurpharma.com/

Latest From Azur Pharma plc

Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication

Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.

Deals Coronavirus COVID-19

Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs

An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.

Deals Financing

NIH To Fund Three Robotic Projects To Improve Health And Quality Of Life

The National Institutes of Health (NIH) plans to provide $2.2 million in funding over the next five years for the development of three innovative "co-robot" projects: an affordable hand-worn device to help the visually impaired grasp objects, a smart-walker to increase mobility in the elderly and a social-robot companion for children. The hand-worn device, which can detect a small object and help the blind user maintain alignment with the object while approaching it, has a global market potential of nearly $20 billion.

Medical Device Innovation

Scrip 100: Robust M&A momentum continues to build

Merger & acquisition (M&A) activity among pharmaceutical and bioscience companies has shown no signs of slowing down. More importantly, even though AstraZeneca's rejection of Pfizer's $120bn plus takeover overture has meant that 2014 cannot boast the largest ever M&A deal, the number of $10bn transactions this year has still surpassed that of 2012 and 2013.

Cancer Orthopedics
See All

Company Information

UsernamePublicRestriction

Register